Varda announces biopharma leader Mikael Dolsten will join board as space-based pharmaceutical manufacturing accelerates. Aug 03, 2026, 06:00 ET The company appoints one of biopharma's most accomplished R&D leaders to its board as it aims to produce the first pharmaceutical made in space for patients on Earth. EL SEGUNDO, Calif., Aug. 3, 2026 /PRNewswire/ - Varda Space Industries announced the appointment of pharmaceutical leader Mikael Dolsten to its board of directors. Dolsten is one of biopharma's most accomplished R&D leaders, having served for 16 years as Chief Scientific Officer and President of Pfizer R&D, where he oversaw the approval of more than 36 medicines and vaccines and advanced more than 150 drug candidates into clinical studies. Throughout his career, Dolsten has played a leading role in translating pioneering science like Varda's into approved medicines, guiding programs from discovery through global development, regulatory approval, and commercialization. "The history of medicine is a history of manufacturing breakthroughs, from fermentation to recombinant proteins, each new environment has expanded what was possible. Varda has built the infrastructure to make orbital manufacturing reliable and repeatable, and I am excited to help translate that capability into medicines that make a difference for patients," said Varda board member Mikael Dolsten. The first space-made product for Earth will be a pharmaceutical, and Varda will be the first to utilize microgravity to deliver novel drugs to benefit patients. Due to the absence of gravity, materials such as the active pharmaceutical ingredients in medicines behave differently than they would on Earth, enabling formulations that would otherwise be impossible to achieve. The company's goal is for in-space pharmaceutical processing to become a normal, reliable part of the drug development pipeline. Varda is now the only company with the launch cadence, reentry capability, and pharmaceutical science team to bring routine space manufacturing to market. "We started Varda with the conviction that the first product manufactured in space and consumed on Earth would be a pharmaceutical," said Varda co-founder and Board Chairman Delian Asparouhov. "Mikael's decades of experience leading drug discovery and development at the highest levels will be invaluable to Varda as we move from proving out the technology to bringing space-made medicines to the market." Since its first mission in 2023, Varda has rapidly increased its flight cadence, completing multiple successful reentry missions with ten launches and reentries planned through 2027. Varda's W-series vehicles, which reach Mach 25 on their return from orbit, offer government and commercial partners a reliable, repeatable, and economical way to return materials and data from space to Earth. As launch cadence across the industry continues to increase, the ability to bring things back will become as foundational as the ability to send them up. About Varda Varda Space Industries is building the infrastructure for a thriving orbital economy, from in-orbit pharmaceutical processing to reliable and economical hypersonic reentry capsules. The company operates out of El Segundo, California with office and industrial production space and has office space in Washington, D.C. and Huntsville, Alabama. Follow Varda on X (@vardaspace), Instagram (@vardaspaceindustries), and LinkedIn. Alex Pearlman, Head of Communications and Marketing: [email protected] SOURCE Varda Space Industries Inc.

Varda Space Industries has appointed Mikael Dolsten, former Chief Scientific Officer and President of Pfizer R&D, to its board of directors. During his 16 years at Pfizer, Dolsten oversaw the approval of more than 36 medicines and vaccines and advanced over 150 drug candidates into clinical studies. Varda aims to produce the first pharmaceutical manufactured in space for patients on Earth. The company leverages microgravity to create drug formulations impossible to achieve on Earth, as materials behave differently without gravity. Since its first mission in 2023, Varda has rapidly increased its flight cadence. The company has planned ten launches and reentries through 2027, using its W-series vehicles that reach Mach 25 on return from orbit.

Beyond the ISS: leaders look to the future of commercial LEO platforms. June 16, 2026 - By Amelia Williamson Smith, Sr. Manager, Scientific Communications & Content This article is part of a series highlighting sessions from the ISS National Lab track at the 2026 ASCEND conference in Washington, D.C. The ISS National Lab hosted a full day of programming highlighting advances in space-based R&D, how the ISS National Lab enables innovation in orbit, and the growing low Earth orbit economy. As the retirement of the International Space Station (ISS) approaches, attention is turning to the future of research and technology development in low Earth orbit (LEO). A session at the 2026 ASCEND conference gathered leaders from across the space industry to discuss how the ISS National Laboratory(R) has helped lay the groundwork for commercial space stations and what is needed to ensure a robust LEO economy in the post-ISS era. "We all recognize there are tremendous opportunities for new avenues of commercialization that we've barely scratched the surface of to date on the ISS," said Lucie Low, chief science officer at Axiom Space, which is developing a commercial space station. "Through the ISS National Lab, we've had this incredible opportunity to do proof-of-concept studies to start getting data." Research on the ISS has driven strong demand for access to space, but the current ecosystem remains nascent. "It's a brittle environment," said Marchel Holle, director of civil space at Varda Space Industries, which is developing autonomous free-flying spacecraft for microgravity R&D and manufacturing. "We would not be where we are without the foundational science, the legacy of the ISS, but we're now seeing a kind of winnowing of microgravity opportunities." When that happens, scientists leave the field, grants are not funded, and companies lose runway, he explained. "Without having a ready access to both crewed and uncrewed facilities, a diversity of platforms, we're not going to see the space economy that I think we all really desperately want." LambdaVision CEO Nicole Wagner - who has conducted nine ISS investigations over the last decade to improve the company's artificial retinas - agrees that sustained access to space is critical. "If we don't keep funding things in space or [keep] underfunding it, you're not maturing the technologies enough to see what's really there, and they're sort of dying on the vine." Addressing recent questions about whether the LEO economy has emerged, Holle emphasized that a strong market exists and the business case closes. He pointed to Varda's recent partnership with United Therapeutics, a $25 billion NASDAQ-listed pharmaceutical company, to manufacture pharmaceuticals in space and noted this is just the beginning. "The key is really bridging into the pharmaceutical industry and having the cadence and the repeat shots on goal needed to speak their language," he said. "We think there are subsets of molecules that have large addressable markets that would really improve the clinical benefit to people here on Earth and that people would be willing to pay for." The panel also discussed the role of an entity like the ISS National Lab after the space station is retired. Michelle Lucas, founder and CEO of Higher Orbits, a nonprofit that enables students to send real experiments to space, stressed that such a role remains "absolutely critical." Without it, researchers, organizations, and small businesses risk losing access to space, she said. "We need a broker...who looks out for the little guys to help aid companies that could develop the next big thing...and organizations developing the workforce pipeline." Ensuring students have continued access to space is essential to building a strong and capable workforce for the future LEO economy, Lucas explained. "You have to invest in your workforce right now, and one of the ways to do that is to give them experiences that inspire them to want to continue." She noted, "Their science may not change the world, but it changes their world, and there's a ripple effect...and it's going to inspire them to go on and do better research." Looking beyond the ISS, panelists see a place for both crewed and uncrewed platforms in LEO. Automation will be important, but humans need to stay in the loop, Low said. "From an R&D perspective, continuous human presence in space is going to be really critical for continuing to build on the science that can be done." Holle agreed there's a strong rationale for maintaining humans in orbit but added that automated platforms offer a more cost-effective solution for certain types of research. The key is incorporating both, he said. "By turning to these diversified models with complementary crewed and free flyers working together, I think you create a dissimilar partnership that's greater than the sum of both components." As the ISS era winds down, one message from the panel was clear: maintaining momentum will require continuity in access, sustained funding, and a diversity of platforms. By building on the strong foundation established over the past two decades, ISS National Lab can help ensure a robust and sustainable future for the LEO economy.